Financial StabilityManagement expects a cash runway into the second half of 2026, indicating financial stability.
Innovative StrategiesAdicet Bio's approach targets CD20, which is different from the majority of peer cell therapy programs that target CD19, showcasing its unique strategy.
Regulatory MilestonesAdicet Bio received Fast Track Designation for ADI-001 for refractory SLE with extrarenal involvement and systemic sclerosis.